- Home
- NVCR
NVCR
NovoCure Limited
as 06-20-2025 4:00pm EST
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
| Founded: | 2000 | Country: | Switzerland |
| Employees: | N/A | City: | ST. HELIER |
| Market Cap: | 1.9B | IPO Year: | 2015 |
| Target Price: | $32.83 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.17 - $34.13 | Next Earning Date: | 07-24-2025 |
| Revenue: | $621,711,000 | Revenue Growth: | 18.27% |
| Revenue Growth (this year): | 5.56% | Revenue Growth (next year): | 9.19% |
Stock Insider Trading Activity of NovoCure Limited (NVCR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Scannell Timothy J | NVCR | Director | Jun 3 '25 | Sell | $17.32 | 999 | $17,299.18 | 6,018 | |
| Madden Martin J. | NVCR | Director | Jun 3 '25 | Sell | $17.19 | 999 | $17,175.61 | 18,674 | |
| Ocean Allyson J | NVCR | Director | Jun 3 '25 | Sell | $17.29 | 999 | $17,269.01 | 3,054 | |
| Hung David | NVCR | Director | Jun 3 '25 | Sell | $17.30 | 999 | $17,279.50 | 12,195 | |
| VERNON W ANTHONY | NVCR | Director | Jun 3 '25 | Sell | $17.35 | 999 | $17,329.25 | 167,887 | |
| HILLEMAN JERYL L | NVCR | Director | Jun 3 '25 | Sell | $17.26 | 999 | $17,246.54 | 5,591 | |
| Stafford Kristin | NVCR | Director | Jun 3 '25 | Sell | $17.28 | 999 | $17,258.92 | 3,054 | |
| LEUNG GABRIEL | NVCR | Director | Jun 3 '25 | Sell | $17.31 | 999 | $17,297.29 | 81,229 | |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Jun 2 '25 | Sell | $18.07 | 30,196 | $528,412.59 | 176,931 | |
| Paravasthu Mukund | NVCR | Chief Operating Officer | May 3 '25 | Sell | $17.91 | 592 | $10,604.20 | 83,556 |
Latest NovoCure Limited News
NVCR Breaking Stock News: Dive into NVCR Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
What Makes NovoCure (NVCR) a New Buy Stock
Zacks
15 days ago
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
MT Newswires
17 days ago
Novocure Insider Sold Shares Worth $528,413, According to a Recent SEC Filing
Benzinga
19 days ago
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
Business Wire
21 days ago
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Motley Fool
24 days ago
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street
Business Wire
25 days ago
Novocure Announces Upcoming Investor Events
Zacks
a month ago
Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?
Compare NVCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVCR NovoCure Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.